MedTrace Logo

RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients

NCT01401075 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2012-11-07

No results posted yet for this study

Summary

Evaluation of safety and efficacy of a standardized mistletoe extract (abnobaVISCUM® Quercus, aVQ) in patients with gastric cancer receiving oral chemotherapy.

Conditions

Interventions

DRUG

mistletoe extract

subcutaneous injections thrice weekly with 1 ml in 4 increasing doses

DRUG

doxifluridine

600 - 900 mg per day orally, depending on weight and status of the patient

Sponsors & Collaborators

  • Abnoba Gmbh

    lead INDUSTRY

Principal Investigators

  • Byung-Sik Kim, Professor · ASAN Medical Center, Seoul

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01401075 on ClinicalTrials.gov